Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ai [Antagonists & Inhibitors]. Found 8 abstracts

Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium.[see comment]. Cell. 2007 Jun 29;129(7):1351-63.
Mu Z, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. The Prostate. 2005 Dec;65(4):331-40.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ai [Antagonists & Inhibitors]

ai [Antagonists & Inhibitors] dt [Drug Therapy] pd [Pharmacology] me [Metabolism] 0 (Antineoplastic Agents) Antineoplastic Agents de [Drug Effects] aa [Analogs & Derivatives] tu [Therapeutic Use] pa [Pathology] Enzyme Inhibitors 0 (Enzyme Inhibitors) Apoptosis ge [Genetics] Human Cisplatin Non-US Gov't Support bi [Biosynthesis] Male Protein-Tyrosine Kinase Phosphorylation Tumor Cell Line 15663-27-1 (Cisplatin) Female EC 2-7-1-112 (Protein-Tyrosine Kinase) ph [Physiology] Cell Division ad [Administration & Dosage] EC 2-7-1-37 (Protein-Serine-Threonine Kinases) NIH Research Support-Extramural Protein-Serine-Threonine Kinases Prostatic Neoplasms Methylnitrosourea rt [Radiotherapy] 154447-36-6 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) en [Enzymology] 53643-48-4 (Vindesine) 0 (Anticarcinogenic Agents) 0 (Tumor Suppressor Protein p53) 363-24-6 (Dinoprostone) Proto-Oncogene Proteins c-kit Neoplasm Metastasis Combined Modality Therapy Sirolimus Mitosis Tumor Suppressor Protein p53 Prostaglandin D2 EC 1-17-4 (Ribonucleotide Reductases) Epidermal Growth Factor) EC 2-7-1-112 (Receptor Monoclonal Antibodies Comparative Study EC 2-7-1 (mTOR protein) 103882-84-4 (gemcitabine) tu [Therapeutic 1406-18-4 (Vitamin E) 1-Phosphatidylinositol 3-Kinase Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Antineoplastic Antimetabolites Protein Kinases Quinazolines EC 2-7-1 (aurora kinase) Gastrointestinal Stromal Tumors EC 2-7-1-37 (proto-oncogene protein akt) Colorectal Neoplasms Pyrimidines 0 (Piperazines) Cultured Tumor Cells Phytogenic Antineoplastic Agents 0 (Transcription Factor AP-1) 7689-03-4 (Camptothecin) North America Ribonucleotide Reductases Phenotype EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Ovarian Neoplasms Chromones Protein Kinase Inhibitors 61-90-5 (Leucine) 0 (cetuximab) Phytogenic) 0 (Antineoplastic Agents Biological) 0 (Tumor Markers 17407-37-3 (vitamin E succinate) 0 (Proto-Oncogene Proteins c-bcl-2) Prostaglandin-Endoperoxide Synthase pc [Prevention & Control] 0 (NF-kappa B) Monoclonal) 0 (Antibodies Antineoplastic Combined Chemotherapy Protocols Platelet-Derived Growth Factor Receptors EC 3-4-22 (Caspases) Proto-Oncogene Proteins Transfection Antisense) 0 (DNA Lung Neoplasms Flow Cytometry Cell Cycle 53123-88-9 (Sirolimus) Inhibitors] EC 2-7-1-112 (Proto-Oncogene Proteins c-kit) 0 (Antineoplastic Combined Chemotherapy Protocols) Anticarcinogenic Agents Mutation Signal Transducing Adaptor Proteins 0 (Quinazolines) 152459-95-5 (imatinib) Small Cell Carcinoma EC 3-4-22 (caspase 7) Cytoplasmic and Nuclear) 0 (Receptors 0 (Carcinogens) 0 (Taxoids) Enzyme Activation Morpholines human) 0 (NEDD9 protein ag [Agonists] Fluorenes Drug Dose-Response Relationship th [Therapy] im [Immunology] Neoplasm Proteins 0 (Proto-Oncogene Proteins) 169590-42-5 (celecoxib) 0 (erlotinib) Antisense DNA 0 (Cyclooxygenase Inhibitors) 33419-42-0 (Etoposide) Transcription Factor AP-1 Drug Synergism 0 (Cyclin-Dependent Kinase Inhibitor p21) 684-93-5 (Methylnitrosourea) Rats Camptothecin Vitamin E Molecular Models Non-US Gov't Research Support NF-kappa B EC 2-7-1-137 (1-Phosphatidylinositol 3-Kinase) 0 (Chromones) Cell Line Non-Small-Cell Lung Carcinoma Carcinogens 35661-60-0 (N-(fluorenyl-9-methoxycarbonyl)leucine) Piperazines Experimental Mammary Neoplasms 0 (Fluorenes) Taxoids Dinoprostone ai [Antagonists & 951-77-9 (Deoxycytidine) Cell Adhesion 0 (15-deoxyprostaglandin J2)
Last updated on Thursday, November 02, 2017